Personalized immune cell therapy plus a CMV vaccine
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to give consent (or have a legal representative).
- Have intermediate or high-grade B-cell non-Hodgkin lymphoma that is CD19-positive, and be in a relapsed or refractory situation where you cannot/choose not to use autologous stem-cell transplant.
- Be CMV-positive on blood testing.
- Be well enough for treatment: life expectancy of at least 16 weeks, KPS score 70 or higher, and enough blood counts (neutrophils, hemoglobin, and platelets).
- Have organ function tests within limits (kidney, liver, and heart function) and no need for extra oxygen to keep saturation above 92%.
- Be able to undergo leukapheresis and later treatments (including lymphodepleting chemotherapy, steroids, and tocilizumab) with no known contraindications; also avoid certain medicines or infections at enrollment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a customized immune-cell treatment (CAR T-cells) plus a vaccine given after stem cell transplant for certain aggressive B-cell non-Hodgkin lymphomas. It aims to help your immune system better recognize and attack the lymphoma and to see how safe the approach is.
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Hear when a new Recurrent B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.